Ryvu Therapeutics (LTS:0RKT) Long-Term Debt: zł72.39 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKT Ryvu Therapeutics SA LTS:0RKT
66 GF Score
Price zł30.25
GF Value zł93.11
! 3 Warning Signs
View Full Analysis

What is Ryvu Therapeutics Long-Term Debt?

Ryvu Therapeutics LTS:0RKT 66 Long-Term Debt is zł72.39 Mil as of Mar. 2026. GuruFocus rates LTS:0RKT with a GF Score™ of 66/100 and a GF Value™ of zł93.11. The stock has 3 warning signs investors should review.

Ryvu Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was zł72.39 Mil.

Ryvu Therapeutics's quarterly Long-Term Debt increased from Sep. 2025 (zł68.90 Mil) to Dec. 2025 (zł70.27 Mil) and increased from Dec. 2025 (zł70.27 Mil) to Mar. 2026 (zł72.39 Mil).

Ryvu Therapeutics's annual Long-Term Debt increased from Dec. 2023 (zł0.00 Mil) to Dec. 2024 (zł64.92 Mil) and increased from Dec. 2024 (zł64.92 Mil) to Dec. 2025 (zł70.27 Mil).

Ryvu Therapeutics  (LTS:0RKT) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Ryvu Therapeutics Long-Term Debt Related Terms

Ryvu Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Ryvu Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ryvu Therapeutics Long-Term Debt Chart

Ryvu Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.74 0.00 0.00 64.92 70.27

Ryvu Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.42 67.05 68.90 70.27 72.39
LTS:0RKT
66GF Score
Ryvu Therapeutics SA LTS:0RKT
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of zł72.39 Mil mean?
Ryvu Therapeutics (LTS:0RKT) has a Long-Term Debt of zł72.39 Mil as of Mar. 2026.
Is Ryvu Therapeutics' Long-Term Debt too high?
Ryvu Therapeutics' current Long-Term Debt is zł72.39 Mil. Overall, Ryvu Therapeutics has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Long-Term Debt compare to VRTX and REGN?
Ryvu Therapeutics' Long-Term Debt of zł72.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Ryvu Therapeutics's current Long-Term Debt is zł72.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Ryvu Therapeutics (LTS:0RKT) has a current Long-Term Debt of zł72.39 Mil. The stock's GF Value™ is zł93.11, compared to a current price of zł30.25 — trading 67.5% below its estimated fair value. The current Long-Term Debt is zł72.39 Mil. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Ryvu Therapeutics (LTS:0RKT), the current Long-Term Debt is zł72.39 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ryvu Therapeutics (LTS:0RKT) Overvalued in 2026?

Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued. The current stock price of zł30.25 is trading 67.5% below its estimated GF Value™ of zł93.11.

Key valuation signals for LTS:0RKT:

  • Long-Term Debt: zł72.39 Mil
  • GF Value™: zł93.11 vs. price of zł30.25 (67.5% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ryvu Therapeutics Business Description

Other Exchanges RVU:Poland9Y4:Germany
Address Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score

Get the complete analysis for LTS:0RKT

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł30.25
Price
zł93.11
GF Value